{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:39:55Z","timestamp":1777531195960,"version":"3.51.4"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,3,13]]},"abstract":"<jats:p> PURPOSE: Recombinant interferon alfa-2b (rIFN\u03b12b) is a standard therapy for chronic myelogenous leukemia (CML). Severe neuropsychiatric toxicity has been described in patients receiving rIFN\u03b12b, although the frequency of and the risk factors for developing this toxicity are not well described. The purpose of this study was to identify predictors for the development of severe neuropsychiatric toxicity in CML patients receiving rIFN\u03b12b-based therapy. <\/jats:p><jats:p> PATIENTS AND METHODS: From a prospective cohort of 91 Philadelphia chromosome\u2013positive, previously untreated, chronic-phase CML patients treated on Cancer and Leukemia Group B (CALGB) 9013, a phase II trial of rIFN\u03b12b plus cytarabine, the following were recorded at baseline: age, sex, race, pretreatment history of neurologic or psychiatric diagnosis, spleen size, blood counts, and peripheral blast count. Best response to treatment, rIFN\u03b12b cumulative dose, dose duration, and dose-intensity were recorded during follow-up. Severe neuropsychiatric toxicity was defined as grade 3 or 4 events, according to CALGB expanded common toxicity criteria. Univariate and multivariate logistic regression analyses were used to identify variables that were associated with the development of severe neuropsychiatric toxicity. <\/jats:p><jats:p> RESULTS: Severe neuropsychiatric toxicity developed in 22 patients (24.0%; 95% confidence interval [CI], 15.2% to 32.8%). Toxicity resolved after withdrawal of treatment in all patients. Five of six patients developed recurrence of symptoms with rechallenge. Twelve (63%) of 19 patients with a pretreatment neurologic or psychiatric diagnosis developed severe neuropsychiatric toxicity, as compared with 10 (14%) of 72 patients without a pretreatment neurologic or psychiatric diagnosis (P = .001), resulting in a relative risk of 4.55 (95% CI, 2.33 to 8.88) for developing severe neuropsychiatric toxicity. No other variables were independently associated with the development of neuropsychiatric toxicity. <\/jats:p><jats:p> CONCLUSION: CML patients with a pretreatment history of a neurologic or psychiatric diagnosis are at significantly increased risk of developing severe neuropsychiatric toxicity during therapy with rIFN\u03b12b plus cytarabine. Monitoring for neuropsychiatric symptoms and avoiding rechallenge are recommended measures for such patients receiving rIFN\u03b12b-based therapy. <\/jats:p>","DOI":"10.1200\/jco.2000.18.6.1301","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:16:39Z","timestamp":1487920599000},"page":"1301-1308","source":"Crossref","is-referenced-by-count":43,"title":["Risk Factors for Severe Neuropsychiatric Toxicity in Patients Receiving Interferon Alfa-2b and Low-Dose Cytarabine for Chronic Myelogenous Leukemia: Analysis of Cancer and Leukemia Group B 9013"],"prefix":"10.1200","volume":"18","author":[{"given":"Martee L.","family":"Hensley","sequence":"first","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer CenterWeill Medical College of Cornell University, and New York Presbyterian Hospital, New York, NY; Cancer and Leukemia Group B Statistical Office, Durham, NC; The University of Chicago, Chicago, IL; and Wayne State University School of Medicine, Detroit, MI."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bercedis","family":"Peterson","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer CenterWeill Medical College of Cornell University, and New York Presbyterian Hospital, New York, NY; Cancer and Leukemia Group B Statistical Office, Durham, NC; The University of Chicago, Chicago, IL; and Wayne State University School of Medicine, Detroit, MI."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer CenterWeill Medical College of Cornell University, and New York Presbyterian Hospital, New York, NY; Cancer and Leukemia Group B Statistical Office, Durham, NC; The University of Chicago, Chicago, IL; and Wayne State University School of Medicine, Detroit, MI."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer CenterWeill Medical College of Cornell University, and New York Presbyterian Hospital, New York, NY; Cancer and Leukemia Group B Statistical Office, Durham, NC; The University of Chicago, Chicago, IL; and Wayne State University School of Medicine, Detroit, MI."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Schiffer","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer CenterWeill Medical College of Cornell University, and New York Presbyterian Hospital, New York, NY; Cancer and Leukemia Group B Statistical Office, Durham, NC; The University of Chicago, Chicago, IL; and Wayne State University School of Medicine, Detroit, MI."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted P.","family":"Szatrowski","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer CenterWeill Medical College of Cornell University, and New York Presbyterian Hospital, New York, NY; Cancer and Leukemia Group B Statistical Office, Durham, NC; The University of Chicago, Chicago, IL; and Wayne State University School of Medicine, Detroit, MI."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-0162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.5.779"},{"key":"R2-0162","doi-asserted-by":"crossref","unstructured":"Gratwohl  A,  Hermans  J  Niederwieser  D, et al:  Bone marrow transplantation for chronic myeloid leukemia:  Long-term results. Bone Marrow Transplant 12:509,1993-516,","DOI":"10.1007\/978-3-642-77083-8_33"},{"key":"R3-0162","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.10.2975.2975"},{"key":"R4-0162","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-4-199502150-00003"},{"key":"R5-0162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.284"},{"key":"R6-0162","doi-asserted-by":"crossref","unstructured":"Kloke  O,  Wando  U,  Opalka  B, et al:  A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia.  Eur J Haematol 48:93,1992-98,","DOI":"10.1111\/j.1600-0609.1992.tb00572.x"},{"key":"R7-0162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403243301204"},{"key":"R8-0162","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92596-1"},{"key":"R9-0162","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.906.906"},{"key":"R10-0162","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(88)90110-5"},{"key":"R11-0162","unstructured":"Silver  RT,  Been  P,  Szatrowski  TP, et al:  Infusional cytosine arabinoside (Ara-C) and recombinant interferon-alpha for the treatment of chronic myeloid leukemia (CML).  Proc Am Soc Clin Oncol 9:209,1990  (abstr)"},{"key":"R12-0162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707243370402"},{"key":"R13-0162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2897"},{"key":"R14-0162","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"R15-0162","unstructured":"Silver  RT,  Szatrowski  TP,  Peterson  B, et al:  Combined alfa-Interferon (rIFN alfa-2B) and low dose cytosine arabinoside (Ara-C) for Ph+ chronic phase chronic myeloid leukemia.  Blood 88:638a,1996  (abstr)"},{"key":"R16-0162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604243141701"},{"key":"R17-0162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.6.948"},{"key":"R18-0162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.26"},{"key":"R19-0162","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V66.6.1352.1352"},{"key":"R20-0162","unstructured":"Italian Cooperative Study Group on Chronic Myeloid Leukemia: A prospective comparison of alfa IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia:  Clinical and cytogenetic results at 2 years in 322 patients. Haematologica 77:204,1992  (abstr)"},{"key":"R21-0162","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.5.1541"},{"key":"R22-0162","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064"},{"key":"R23-0162","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.5.1541"},{"key":"R24-0162","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811215)48:12<2577::AID-CNCR2820481207>3.0.CO;2-Z"},{"key":"R25-0162","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410140505"},{"key":"R26-0162","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.10.1475"},{"key":"R27-0162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.4.571"},{"key":"R28-0162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.10.1563"},{"key":"R29-0162","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1983.63"},{"key":"R30-0162","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03350070056026"},{"key":"R31-0162","unstructured":"Mattson  K,  Niiranen  A,  Iivanainen  M, et al:  Neurotoxicity of interferon.  Cancer Treat Rep 67:958,1983-961,"},{"key":"R32-0162","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.5.672"},{"key":"R33-0162","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370090055011"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.6.1301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:42:45Z","timestamp":1653514965000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.6.1301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3,13]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,3,13]]}},"alternative-id":["10.1200\/JCO.2000.18.6.1301"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.6.1301","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3,13]]}}}